Outcome of Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01623700|
Recruitment Status : Unknown
Verified May 2011 by Uppsala University.
Recruitment status was: Active, not recruiting
First Posted : June 20, 2012
Last Update Posted : June 20, 2012
This observational study will based on the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) and the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) which since 2009 are merged into The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART).
The aim of this study is to investigate the impact of different antithrombotic treatment options (treatment duration, type of treatment and combination of treatments) in Acute Coronary Syndrome (ACS) patients on outcomes such as recurrent ischemic events and mortality.
|Condition or disease|
|Acute Coronary Syndrome Myocardial Infarction|
|Study Type :||Observational|
|Actual Enrollment :||78000 participants|
|Official Title:||A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients|
|Study Start Date :||January 2006|
|dual antiplatelet treatment 12 months after ACS event|
|dual antiplatelet treatment 6 months after ACS event|
|dual antiplatelet treatment 3 months after ACS event|
- number of patients with adverse events in patient groups with different antithrombotic treatment strategies [ Time Frame: up to 5 years and 6 months ]adverse events such as: mortality, re-infarction, revascularization, ischemic- and non-ischemic stroke and bleeding
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01623700
|Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University|
|Uppsala, Uppsala County, Sweden, 75237|
|Principal Investigator:||Stefan James, MD, PhD||Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology|